Literature DB >> 30380077

Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania.

Martha F Mushi1, Oliver Bader2, Christine Bii3, Uwe Groß2, Stephen E Mshana1.   

Abstract

Despite the increased burden of human immunodeficiency virus (HIV) and other comobidities in developing countries, information regarding antifungal susceptibility patterns of Candida spp. and their virulence potential are still limited. Here, we report the virulence and antifungal susceptibility patterns of Candida spp. from varieties spectrum of candidiasis in a tertiary hospital, Tanzania. The study was conducted from March to December 2017. Candida spp. from clinical samples were characterized. Antifungal susceptibility patterns based on EUCAST guidelines and virulence activities (phospholipase, protease, hemolysin, and coagulase activity) were determined. A total of 399 Candida spp. isolates were obtained, of these, 278, 51 and 47 were C. albicans, C. tropicalis, and C. glabrata, respectively. Phospholipase 193/268, protease 32/51 and coagulase 25/47 were the most frequently detected virulence activities in C. albicans, C. tropicalis, and C. glabrata, respectively. Protease and phospholipase were frequently detected virulence activities from C. albicans from blood and esophageal brushes. The median zone diameter of protease activities was significantly larger among C. tropicalis than C. albicans. C. albicans, and C. tropicalis isolates were 100% sensitive to caspofungin. The proportions of C. albicans isolate resistant to fluconazole, voriconazole and posaconazole were 3.1, 3.6%, and 1.8%, respectively. In conclusion, the majority of Candida spp. isolates were sensitive to fluconazole. There are different phenotypes of C. albicans, C. glabrata and C. tropicalis based on susceptibility and virulence activities patterns, necessitating further molecular characterizations to place them in global perspective. Routine antifungal susceptibility testing to guide clinical therapy should be encouraged in developing countries.

Entities:  

Year:  2018        PMID: 30380077     DOI: 10.1093/mmy/myy107

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  3 in total

1.  Two New 1,3,4-Oxadiazoles With Effective Antifungal Activity Against Candida albicans.

Authors:  Isis Regina Grenier Capoci; Karina Mayumi Sakita; Daniella Renata Faria; Franciele Abigail Vilugron Rodrigues-Vendramini; Glaucia Sayuri Arita; Admilton Gonçalves de Oliveira; Maria Sueli Felipe; Bernard Maigret; Patricia de Souza Bonfim-Mendonça; Erika Seki Kioshima; Terezinha Inez Estivalet Svidzinski
Journal:  Front Microbiol       Date:  2019-09-12       Impact factor: 5.640

2.  Candida vaginitis among symptomatic pregnant women attending antenatal clinics in Mwanza, Tanzania.

Authors:  Martha F Mushi; Amani Mmole; Stephen E Mshana
Journal:  BMC Res Notes       Date:  2019-11-27

3.  Oral candidiasis in HIV-uninfected pediatric population in areas with limited fungal diagnosis: A case study from a tertiary hospital, Tanzania.

Authors:  Martha F Mushi; Neema Loi; Stephen E Mshana
Journal:  Ther Adv Infect Dis       Date:  2021-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.